Posted on: December 8, 2011 by Jonathan Marino
Lately, there’s been a whole lot of bemoaning of this and that to explain why VCs are abandoning the biotech and device space and why strategics are slowing early-stage funding. Lawmakers and regulators have made it too tough to IPO. Lawmakers and regulators have made it too tough to get anything approved at the FDA. [...]
Tags: Draper Fisher Jurvetson, Fidelity Biosciences, GE, Google Ventures, Johnson & Johnson Development Corp., New Enterprise Associates, OrbiMed Advisors, Thuja Capital, Versant Ventures
Posted on: November 17, 2011 by cnolan
Swiss biotech start-up Biocartis has raised 71 million euro ($100 million) in Series C financing. Investors in the round include Debiopharm Group, Philips, Johnson & Johnson Development Corp., the Wellcome Trust, Korys, Valiance and Biovest. The money will be used to help commercialize the company’s compact molecular diagnostics system.
Tags: Debiopharm Group, Johnson & Johnson Development Corp., Korys, Philips, The Wellcome Trust, Valiance